IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Resistance to HIV Infection
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The immune systems of some individuals may be capable of resisting HIV infection. These individuals do not appear to be infected with HIV despite multiple sexual encounters with HIV infected partners. This study will examine the immune systems of these individuals to determine what factors are responsible for their ability to resist HIV infection.
Study hypothesis: Some long-term, multiply-exposed seronegative persons have relative resistance to HIV infection maintained by T cell responses.
| Condition |
|---|
| HIV Infections |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective |
| Official Title: | Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals |
| Estimated Enrollment: | 100 |
| Study Start Date: | December 1995 |
Rare individuals appear naturally resistant to overt HIV-1 infection despite repeated sexual exposures. These individuals, referred to as exposed seronegatives (ES), represent a unique population in which to evaluate mechanisms by which HIV-1 replication is either controlled or aborted. The purpose of the study is to analyze HIV-specific immune responses, both cellular and humoral, that exist in seronegative individuals who have experienced multiple exposures to HIV by sexual contact.
This study will follow participants for 2 years. Participants will have 25 study visits during the study. Assessments will include HIV tests, viral load measurements, CD4 counts, pregnancy tests, and physical exams.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Good general health
- HIV uninfected
- Repeated exposures to HIV through unprotected sexual intercourse within the 2 years prior to study entry
- Live in the greater Seattle area
- Plan to stay in the greater Seattle area for the 2 years after study entry
Exclusion Criteria:
- Pregnancy
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00069485
| United States, Washington | |
| Fred Hutchinson Cancer Research Center / University of Washington HIV Vaccine Trials Unit | Recruiting |
| Seattle, Washington, United States, 98104 | |
| Contact: Kim Louis 206-667-2300 klouis@fhcrc.org | |
| Principal Investigator: | Julie McElrath, MD, PhD | University of Washington |
More Information
| ClinicalTrials.gov Identifier: | NCT00069485 History of Changes |
| Other Study ID Numbers: |
5R01AI047086-03 ( US NIH Grant/Contract Award Number ) |
| Study First Received: | September 26, 2003 |
| Last Updated: | September 17, 2007 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
HIV Seronegativity |
Additional relevant MeSH terms:
|
Infection HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on June 27, 2017